BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

APEIRON Biologics AG Establishes Biotech-Spinoff Attoquant Diagnostics


12/4/2012 11:55:18 AM

Vienna, 4 December 2012: APEIRON Biologics AG (Apeiron) today announced the launch of Attoquant Diagnostics GmbH (Attoquant) as a subsidiary. Attoquant will globally commercialize its already successfully marketed peptide analytics service RAS-FingerprintTM and further develop the underlying platform technology.

Vienna-based biotech company APEIRON Biologics AG (Apeiron) today announced the establishment of a subsidiary that will globally commercialize the peptide analytics service RAS-FingerprintTM which has been developed by Apeiron and already marketed successfully. Attoquant Diagnostics GmbH (Attoquant) has been founded specifically for that purpose and will also be responsible for further development of the technology platform as well as the extension of the product range.

Attoquant offers a globally unique technology to measure and quantify all peptides of the renin angiotensin system (RAS) from blood and various tissues with extraordinary sensitivity. These peptides play a key role e.g. for the regulation of blood pressure, water balance as well as acute and chronic inflammation. The simultaneous and precise analytical assessment of the entirety of these peptides is worldwide unique and was termed RAS-FingerprintTM. This novel technology may be used for a more targeted application of drugs that lower high blood pressure or to newly develop such medications by rational design. Moreover, the RAS-FingerprintTM allows for a better understanding of prevention and treatment of cardiovascular and renal diseases and has great potential as a diagnostic and therapeutic biomarker in general. Attoquant is also working on extensions of the methodology and is offering client-specific analytics.

Hans Loibner, PhD, CEO of Apeiron: "We are very pleased to provide to a young and entrepreneurial team the opportunity to start up another outstanding biotech company in Austria, based on a promising new technology. This technology was developed as part of pharmacologic assays within the project APN01 that was successfully out-licensed to GlaxoSmithKline in 2010. It has manifold possible applications in preclinical and particularly in clinical R&D."

Marko Poglitsch, CEO of Attoquant: "After the first successfully established customer relations, Attoquant is glad to give valuable input into the further development of diagnostics and therapy of various cardiovascular diseases. While we presumed that our technology will be a useful tool in particular for drug development and personalized medicine, we were surprised by the extent of positive feedback from the scientific community. Now, our mission is to make the RAS-FingerprintTM broadly available for basic research and clinical studies and to further develop it for its use in routine diagnostics. In view of these tasks, we have very exciting months and years ahead."

About Apeiron (as of December 2012):

Apeiron is a mostly privately financed biotech company in Vienna that develops immunological/biological therapies against cancer. Its portfolio consists of five clinical projects (lead in phase III) as well as some preclinical approaches. The most advanced project APN311 is an antibody to treat the pediatric cancer neuroblastoma. The immunocytokine hu14.18-IL2 (APN301) is being developed clinically in neuroblastoma as well as in melanoma. Moreover, recombinant human superoxide dismutase is in clinical development, notably in a topical liposomal formulation (APN201) as a potent anti-inflammatory tissue-protective biologic. Two complementary approaches are pursued (APN401, APN411) that stimulate immune cells in a novel way to treat cancer more effectively. The recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, previously APN01) was licensed out to GlaxoSmithKline in early 2010 and is currently investigated in a phase II trial in patients suffering from acute lung injury. Apeiron started operations in 2006 and has 23 employees as of today.

About Attoquant (as of December 2012):

Attoquant Diagnostics GmbH is a provider of analytical services and based in Vienna. It offers the highly sensitive quantification of peptides in blood or tissues via its newly developed technology based on LC-MS/MS (liquid chromatography / mass spectroscopy). Even in minimal amounts, these peptides carry important physiological roles. The current focus lies on the peptide hormones of the renin angiotensin system. Attoquant is a subsidiary of APEIRON Biologics AG and currently has five employees.

About the RAS-FingerprintTM (as of December 2012):

The RAS-FingerprintTM is the name of a technology for simultaneous quantification of up to ten peptide hormones of the renin angiotensin system (plus other peptides). Thus, a precise "fingerprint" of this hormone system is created that is both patient- and therapy-specific. Developed over the last few years, this proprietary technology is based on a special method of sample preparation for the subsequent analysis by mass spectroscopy and has a sensitivity and comprehensiveness that is globally unique.

Contact Apeiron:

Dr. Hans Loibner, CEO

Campus-Vienna-Biocenter 5

1030 Vienna, Austria

T +43 / (0)1 / 865 65 77

E apeiron@apeiron-biologics.com

W www.apeiron-biologics.com

Contact Attoquant:

DI Marko Poglitsch, CEO

Campus-Vienna-Biocenter 5

1030 Vienna, Austria

T +43 / (0)1 / 865 65 77 121

E marko.poglitsch@attoquant.com

W www.attoquant.com

Copy Editing & Distribution:

PR&D - Public Relations for Research & Education Mariannengasse 8 1090 Vienna, Austria T +43 / (0)1 / 505 70 44 E

contact@prd.at W www.prd.at



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES